Atlas Trials

AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer

Clinical trial NCT07712094 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07712094
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroendocrine Cancer
Start date
2026-08-01
Primary completion
2029-02-27
Enrollment
56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.